Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease

Abstract The primary objective of this study was to evaluate how schizophrenia (SCH) spectrum disorders and applied antipsychotic (AP) treatment affect serum level of amino acids (AAs) and biogenic amines (BAs) in the early course of the disorder. We measured 21 different AAs and 10 BAs in a sample...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Madis Parksepp, Liisa Leppik, Kadri Koch, Kärt Uppin, Raul Kangro, Liina Haring, Eero Vasar, Mihkel Zilmer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/29a5ddd501d349ad867fc08c7190aed6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29a5ddd501d349ad867fc08c7190aed6
record_format	dspace
spelling	oai:doaj.org-article:29a5ddd501d349ad867fc08c7190aed62021-12-02T18:51:51ZMetabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease10.1038/s41598-020-71014-w2045-2322https://doaj.org/article/29a5ddd501d349ad867fc08c7190aed62020-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-71014-whttps://doaj.org/toc/2045-2322Abstract The primary objective of this study was to evaluate how schizophrenia (SCH) spectrum disorders and applied antipsychotic (AP) treatment affect serum level of amino acids (AAs) and biogenic amines (BAs) in the early course of the disorder. We measured 21 different AAs and 10 BAs in a sample of antipsychotic (AP)-naïve first-episode psychosis (FEP) patients (n = 52) at baseline, after 0.6-year as well as after 5.1-year treatment compared to control subjects (CSs, n = 37). Serum levels of metabolites were determined with AbsoluteIDQ p180 kit using flow injection analysis tandem mass spectrometry and liquid chromatography technique. Elevated level of taurine and reduced level of proline and alpha-aminoadipic acid (alpha-AAA) were established as metabolites with significant change in AP-naïve FEP patients compared to CSs. The following 0.6-year treatment restored these alterations. However, further continuous 5.1-year AP treatment changed the metabolic profile substantially. Significantly elevated levels of asparagine, glutamine, methionine, ornithine and taurine, alongside with decreased levels of aspartate, glutamate and alpha-AAA were observed in the patient group compared to CSs. These biomolecule profile alterations provide further insights into the pathophysiology of SCH spectrum disorders and broaden our understanding of the impact of AP treatment in the early stages of the disease.Madis ParkseppLiisa LeppikKadri KochKärt UppinRaul KangroLiina HaringEero VasarMihkel ZilmerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Madis Parksepp Liisa Leppik Kadri Koch Kärt Uppin Raul Kangro Liina Haring Eero Vasar Mihkel Zilmer Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease
description	Abstract The primary objective of this study was to evaluate how schizophrenia (SCH) spectrum disorders and applied antipsychotic (AP) treatment affect serum level of amino acids (AAs) and biogenic amines (BAs) in the early course of the disorder. We measured 21 different AAs and 10 BAs in a sample of antipsychotic (AP)-naïve first-episode psychosis (FEP) patients (n = 52) at baseline, after 0.6-year as well as after 5.1-year treatment compared to control subjects (CSs, n = 37). Serum levels of metabolites were determined with AbsoluteIDQ p180 kit using flow injection analysis tandem mass spectrometry and liquid chromatography technique. Elevated level of taurine and reduced level of proline and alpha-aminoadipic acid (alpha-AAA) were established as metabolites with significant change in AP-naïve FEP patients compared to CSs. The following 0.6-year treatment restored these alterations. However, further continuous 5.1-year AP treatment changed the metabolic profile substantially. Significantly elevated levels of asparagine, glutamine, methionine, ornithine and taurine, alongside with decreased levels of aspartate, glutamate and alpha-AAA were observed in the patient group compared to CSs. These biomolecule profile alterations provide further insights into the pathophysiology of SCH spectrum disorders and broaden our understanding of the impact of AP treatment in the early stages of the disease.
format	article
author	Madis Parksepp Liisa Leppik Kadri Koch Kärt Uppin Raul Kangro Liina Haring Eero Vasar Mihkel Zilmer
author_facet	Madis Parksepp Liisa Leppik Kadri Koch Kärt Uppin Raul Kangro Liina Haring Eero Vasar Mihkel Zilmer
author_sort	Madis Parksepp
title	Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease
title_short	Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease
title_full	Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease
title_fullStr	Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease
title_full_unstemmed	Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease
title_sort	metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/29a5ddd501d349ad867fc08c7190aed6
work_keys_str_mv	AT madisparksepp metabolomicsapproachrevealedrobustchangesinaminoacidandbiogenicaminesignaturesinpatientswithschizophreniaintheearlycourseofthedisease AT liisaleppik metabolomicsapproachrevealedrobustchangesinaminoacidandbiogenicaminesignaturesinpatientswithschizophreniaintheearlycourseofthedisease AT kadrikoch metabolomicsapproachrevealedrobustchangesinaminoacidandbiogenicaminesignaturesinpatientswithschizophreniaintheearlycourseofthedisease AT kartuppin metabolomicsapproachrevealedrobustchangesinaminoacidandbiogenicaminesignaturesinpatientswithschizophreniaintheearlycourseofthedisease AT raulkangro metabolomicsapproachrevealedrobustchangesinaminoacidandbiogenicaminesignaturesinpatientswithschizophreniaintheearlycourseofthedisease AT liinaharing metabolomicsapproachrevealedrobustchangesinaminoacidandbiogenicaminesignaturesinpatientswithschizophreniaintheearlycourseofthedisease AT eerovasar metabolomicsapproachrevealedrobustchangesinaminoacidandbiogenicaminesignaturesinpatientswithschizophreniaintheearlycourseofthedisease AT mihkelzilmer metabolomicsapproachrevealedrobustchangesinaminoacidandbiogenicaminesignaturesinpatientswithschizophreniaintheearlycourseofthedisease
_version_	1718377375793676288

Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease

Ejemplares similares